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Tuberculosis (TB) has troubled mankind for millennia, but current treatment strategies are 
long and complicated and the disease remains a major global health problem. The risk of 
Mycobacterium tuberculosis (Mtb) infection or progression of active TB disease is elevated 
in individuals with vitamin D deficiency. High-dose vitamin D was used to treat TB in the 
pre-antibiotic era, and in vitro experimental data show that vitamin D supports innate immune 
responses that restrict growth of Mtb. Several randomised controlled trials have tested 
whether adjunctive vitamin D supplementation enhances the clinical and microbiological 
response to standard antimicrobial chemotherapy for pulmonary TB. The effects have been 
modest at best, and attention is turning to the question of whether vitamin D supplementation 
might have a role in preventing acquisition or reactivation of latent Mtb infection. In this 
article, we describe the effects of vitamin D on host immune responses to Mtb in vitro and in 
vivo, and review the results of clinical trials in the field. We also reflect on the findings of 
clinical trials of vitamin D supplementation for the prevention of acute respiratory tract 
infections, and discuss how these findings might influence the design of future trials to 
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Introduction 
Mycobacterium tuberculosis (Mtb) is a highly successful intracellular bacterium that is an 
elusive challenge to the human immune system. Where Mtb manages to subvert host 
immunity, it is either maintained in a latent state or the infection progresses to cause active 
tuberculosis (TB) disease, which is most commonly manifested in the lung. A delicate 
immunological balance between the pathogen and the host will ultimately decide the outcome 
of infection and disease. Before the discovery of antibiotics with anti-mycobacterial activity, 
TB patients were isolated in sanatoria to receive open-air treatment with the rationale that 
bed-rest, fresh air, sunlight and good nutrition would strengthen the immune system and 
result in clinical improvement [1, 2]. Although no randomized clinical trials were ever 
performed to evaluate potential benefits of open-air treatment, clinical evidence of TB 
improvement was reported by many clinicians [1, 2]. An investigation from 1916 
demonstrated that almost half of the TB patients who were admitted to a sanatoria died within 
5 years, while the health condition in 56% of the patients was actually improved [1]. 
Likewise, an unblinded two-arm study including 1077 patients with a clinical diagnosis of 
pulmonary TB at the Royal Brompton Hospital in the UK in 1848, demonstrated that in half 
of the cohort who received a daily intake of cod liver oil, the disease was more often arrested 
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Nowadays, TB is treated using drugs with direct anti-mycobacterial activity ie. inhibition of 
cell wall synthesis, protein synthesis or RNA transcription etc. By contrast, host-directed 
therapies can influence clinical outcomes by regulating the immune response to Mtb. Vitamin 
D has received a lot of attention as a potential host-directed therapy by virtue of its 
immunomodulatory properties, including induction of innate antimicrobial effector responses 
as well as anti-inflammatory pathways that can dampen pathological inflammation in TB. 
While vitamin D has a well-established role to promote bone health and calcium homeostasis, 
a growing body of epidemiological evidence suggests that it also exerts ‘non-classical effects’ 
including modulation of immune responses [4]. Population studies indicate that low 
circulating levels of 25-hydroxyvitamin D (25(OH)D) in peripheral blood, indicating vitamin 
D deficiency or insufficiency, are common, and that low 25(OH)D associates independently 
with susceptibility to numerous clinical conditions [5-7]. Such associations have been 
reported for a wide range of infections [8], active TB included [9-13]. Importantly, intake of 
vitamin D occurs via exposure of the skin to UVB radiation in sunshine (which simulates 
cutaneous vitamin D synthesis) or oral ingestion of foods or supplements that contain vitamin 
D. In the tropics, sun exposure is usually enough to sustain adequate levels of 25(OH)D in the 
circulation year-round, but at higher latitudes UVB is of insufficient intensity to support 
cutaneous production of vitamin D during winter [14]. It is tempting to speculate that in the 
pre-antibiotic era, clinical recovery observed in many TB patients who received heliotherapy 
or cod liver oil supplements (rich in vitamin D), could partly be due to the positive effects of 
vitamin D on the host response to Mtb. This raises the question whether vitamin D 
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Vitamin D-mediated effects on anti-mycobacterial immunity in vitro 
As illustrated in Figure 1, vitamin D metabolism involves both endocrine and paracrine 
systems (Figure 1). In vivo, vitamin D produced in the skin or ingested in the diet undergoes 
hepatic conversion to its major circulating metabolite 25(OH)D, whose concentration in 
serum or plasma is the accepted measure of vitamin D status. 25(OH)D then undergoes a 
further hydroxylation step, catalyzed by the 25(OH)D converting enzyme 1-hydroxylase 
(CYB27B1) to form the active metabolite and steroid hormone 1,25-dihydroxyvitamin D 
(1,25(OH)2D) [15]. The 25(OH)D proform is primarily synthesized in the liver, although 25-
hydroxylation has also been reported to occur in leucocytes [15]. Bioactive 1,25(OH)2D is 
mainly produced in the kidney, but also in a number of other tissues including immune cells 
such as macrophages, lymphocytes and dendritic cells (DC) [15]. Vitamin D signaling is 
triggered by binding of active 1,25(OH)2D to the intracellular vitamin D receptor (VDR), 
generating a transcription factor that can bind to specific sites in the DNA called vitamin D 
response elements (VDREs). The 1,25(OH)2D/VDR complex can modulate the expression of 
different target genes including the antimicrobial peptide, hCAP-18, which is the sole human 
cathelicidin [16-18]. Antimicrobial peptides are small cationic molecules with the ability to 
interact with and kill different pathogens primarily in skin and at mucosal surfaces [19]. LL-
37 is the cleavage product produced from hCAP-18, which is an antimicrobial peptide that is 
largely produced by neutrophils and epithelial cells; it is also expressed in macrophages that 
are the main host cell in which Mtb resides. In human cells grown in vitro, 25(OH)D can 
support Mtb-induced expression of LL-37 in macrophages [9] and epithelial cells [20] and 
this increased expression of LL-37 restricts Mtb growth in alveolar macrophages in the lung. 
Interestingly, the VDREs present in the promoters of many human genes, i.e. cathelicidin 
(CAMP) are missing from rodent genes and therefore data on vitamin D signaling in mouse 
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 In the mid-1980s, it was first discovered that 25(OH)D and 1,25(OH)2D could reduce 
intracellular growth of Mtb in human monocytes [22] and macrophages [23] in vitro. 
Incubation of monocyte-derived macrophages with recombinant IFN- augmented the 
activity of 1-hydroxylase in the cells, which promoted the conversion of the 25(OH)D 
proform to the active 1,25(OH)2D metabolite [22]. Subsequently, it was reported that toll-like 
receptor (TLR) 2/1 activation on human Mtb-infected macrophages triggered an 
antimicrobial pathway that was dependent on both the endogenous production and action of 
1,25(OH)2D via the VDR [9]. Apparently, TLR 2/1 ligation up-regulated expression of the 
VDR as well as the 1-hydroxylase genes, leading to induction of LL-37 and restricted 
growth of Mtb [9, 24]. In line with these in vitro findings, patients with chronic TB and 
severe vitamin D deficiency expressed low levels of LL-37 in situ in granulomatous tissue 
obtained from Mtb-infected lungs [25].  
 
Inhibition of hCAP-18 expression in a vitamin D-treated human monocytic cell line using 
small interfering RNA (siRNA) demonstrated that growth of the avirulent Mtb strain H37Ra, 
was completely restored compared with a non-specific siRNA control, suggesting that LL-37 
is essential for antimicrobial activity against Mtb in mononuclear phagocytes [24]. However, 
other studies have shown that vitamin D-mediated effects in human cells may involve other 
antimicrobial effector functions such as induction of nitric oxide synthase (iNOS) [26] or 
oxidative burst [26, 27], while vitamin D can also counteract Mtb-induced inhibition of 
phagolysosomal fusion [28, 29] in macrophages. In addition, 1,25(OH)2D can induce IL-1 
expression in Mtb-infected cells and promote an IL-1-driven production of human -
defensin-2 by adjacent epithelial cells [30]. Another important defence mechanism promoted 
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phagolysosomal maturation and degradation of intracellular pathogens including Mtb, and 
thus can overcome the phagosome-lysosome fusion arrest induced by Mtb [32]. In human 
monocytes, mycobacterial lipoproteins trigger autophagy by activation of TLR2/1, CD14 and 
VDR signaling [33]. In line with these findings, Rekha and colleagues recently demonstrated 
that 1,25(OH)2D, alone or in combination with the histone deacetylase inhibitor 
phenylbutyrate, counteracted Mtb-induced suppression of LL-37 as well as autophagy-related 
markers and restricted Mtb growth in human macrophages in vitro [34]. Notably, silencing of 
LL-37 expression blocked autophagy, suggesting that induction of autophagy was dependent 
on LL-37 [34]. Likewise, it has been shown that oral administration of vitamin D, or vitamin 
D in combination with phenylbutyrate, to healthy individuals reduced Mtb growth in 
monocyte-derived macrophages ex vivo [35]. Several in vitro findings support synergistic 
effects of combination treatment with vitamin D and phenylbutyrate including antimicrobial 
and anti-inflammatory responses to both enhance bacterial clearance and resolve 
immunopathology [20, 34, 36]. 
 
Overall, in vitro and ex vivo findings suggest that vitamin D-mediated innate immunity can 
contribute to control of Mtb infection via the induction of LL-37 and also other antimicrobial 
mechanisms, such as induction of reactive nitrogen and oxygen intermediates as well as 
autophagy in human macrophages. These pro-inflammatory actions have potential to cause 
immunopathology as well as protection: however, there is also evidence that vitamin D can 
simultaneously exert anti-inflammatory effects that have potential to regulate inflammation. 
 
Vitamin D-mediated effects on anti-inflammatory responses 
Apart from the described effects on antimicrobial immunity in TB, vitamin D has also been 
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inflammatory responses that could contribute to disease amelioration and decrease the risk of 
mortality (Figure 2). While 1,25(OH)2D stimulates maturation and activation of human 
monocytes and macrophages in vitro, studies on other antigen-presenting cells such as DCs 
show opposite effects. VDR agonists including 1,25(OH)2D [37], and its synthetic analogs 
[38, 39] inhibited the differentiation, maturation, activation as well as survival of monocyte-
derived DCs. This resulted in decreased IL-12 and enhanced IL-10-production in mature DCs 
and reduced proliferation of alloreactive CD4
+
 T cells [40]. Instead, it has been observed that 






 regulatory T 
(Treg) cells with suppressive properties that can be recruited to sites of inflammation [41, 
42]. Tolerogenic DCs could also be induced by virulent Mtb strains and may induce 
functional inactivation of effector T cells [43]. Further studies investigating the role of 
1,25(OH)2D on modulation of DC function and Mtb-specific immune responses in vivo are 
warranted to understand the balance between good (anti-inflammatory) and bad 
(immunosuppressive) DC polarization.  
 
In vitro studies have shown that vitamin D can inhibit transcription factors involved in 
cytokine gene regulation including Nuclear Factor of Activated T cells (NFAT), Activator 
Protein 1 (AP-1) and Nuclear Factor kappa B (NF-κB) [44-46], which result in less 
production of Th1 cytokines such as IFN-, IL-12, and TNF- by T cells and macrophages 
[18, 47, 48]. Furthermore, IFN-γ up-regulated 1α-hydroxylase and thus enhanced production 
of 1,25(OH)2D, while IL-4 induced catabolism of 25(OH)D to the inactive metabolite 
24,25D(OH)2D via the 24-hydroxylase (CYP24A1) [49]. These results suggest that adaptive 
cell-mediated immune responses induced by vitamin D, may regulate innate antimicrobial 
mechanisms used to control Mtb infection. As such, 1,25(OH)2D can suppress key effector 
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[50]. Moreover, 1,25(OH)2D may down-regulate pattern recognition receptors such as TLR2, 
TLR4, dectin-1 and mannose receptor on Mtb-infected macrophages [51], and instead 
promote induction of immunosuppressive mediators, such as IL-10 and prostaglandin E2 
(PGE2) from Mtb-infected peripheral blood mononuclear cells (PBMCs) [52].  
 
Studies on both human and mouse cells support that 1,25(OH)2D contribute to the generation 
of in vitro induced IL-10 producing Treg cells [53]. PBMCs from TB patients and controls 





 Treg cells that were inversely correlated to the levels of inflammatory 
chemokines MCP-1, MIP-1β and CXCL10 [54]. High serum levels of IFN--inducible 
CXCL10 is associated with enhanced T cell infiltration and progression of active TB [55] and 
CXCL10 is also a risk factor for development of TB-IRIS (TB-immune reconstitution 
inflammatory syndrome) [56]. Immunomodulatory effects of vitamin D supplementation in 
vivo involved enhanced resolution of lymphopenia, monocytosis, as well as a reduced pro-
inflammatory cytokine/chemokine cascade [57]. Accordingly, vitamin D contributed to an 
elevated lymphocyte:monocyte ratio [58, 59] that has been shown to correlate with immune 
protection in TB. Vitamin D treatment also reduced a number of inflammatory mediators 
including CXCL9, CXCL10, MMP-9, LL-37, IL-6, IL-12, TNF and IL-10 [57]. A decrease 
of LL-37 and IL-10 contrasts in vitro data on vitamin D-induced effects, but may result as a 
consequence of enhanced TB control and reduced systemic inflammation. High serum levels 
of LL-37 in patients with active TB correlated with sputum smear positivity [60], which may 
reflect the acute phase response as a whole, rather than the induction of antimicrobial LL-37 
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In vitro studies using Mtb-infected leukocytes or PBMCs from TB patients and controls 
stimulated with Mtb-antigens, suggested that 1,25(OH)2D can down-regulate Mtb-induced 
expression of several matrix metalloproteinases (MMPs) known to be associated with tissue 
remodeling and TB granuloma formation [52, 61]. In a recent study using an organotypic 
lung tissue model, it was also demonstrated that global inhibition of MMPs expressed by 
macrophages and epithelial cells could prevent early granuloma formation and Mtb growth in 
the tissue [62]. Another interesting in vitro study recently demonstrated that parent vitamin D 
as well as the 25(OH)D proform and active 1,25(OH)2D, contributes to maintaining or 
enhancing endothelial stability and barrier function in the presence of pro-inflammatory 
mediators via a mechanism that is not the result of conversion to 1,25(OH)2D, but 
independent from canonical VDR signaling [63]. Disruption of endothelial stability and an 
enhanced vascular leakage caused by inflammation, may enhance disease progression in 
several inflammatory disorders that are typically associated with low vitamin D status. It has 
also been suggested that vitamin D-induced effects are dependent on the multiplicity of Mtb 
infection (MOI), as 1,25(OH)2D restricted bacterial growth by macrophages at low MOIs, 
while it mainly reduced host cytotoxicity at high MOIs [64].   
 
These results support a role of active vitamin D in reducing host inflammation and tissue 
damage that could help in resolution of cavities in the Mtb-infected lung. But while it is 
important to reduce overt inflammation in TB, it is as important to enhance specific TB 
immunity and avoid local immunosuppression. Additional knowledge that could support 
our understanding of vitamin D-mediated effects include studies of Mtb-exposed DC and 
how these regulate T cell activation. More detailed analyses of the functional activity in 
central memory and effector memory T cells as well as the prevalence of Treg cells in 
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response to vitamin D. While most in vitro studies involve the laboratory Mtb strain, 
H37Rv, testing clinical isolates and primarily the impact of multidrug-resistant TB (MDR-
TB) on vitamin D responsiveness, and how this is affected by standard antibiotics also 
need to be resolved. However, in order to select the best regimen of vitamin D 
supplementation for clinical intervention studies, there are a number of issues relating to 
vitamin D metabolism and dosing that should be considered.  
 
Vitamin D metabolites, blood concentrations and dosing 
In recent years it has become clear that circulating concentrations of parent vitamin D 
(cholecalciferol or ergocalciferol) and the 25(OH)D proform may be important for efficient 
production of bioactive 1,25(OH)2D [65]. The half-life of parent vitamin D is short i.e. 12-
24h [66], and also the 1,25(OH)2D form appears as a transient metabolite with a short half-
life of 4-6h [67]. The 25(OH)D metabolite has a half-life of about 3 weeks, and is therefore 
the most abundant circulating form of vitamin D that is also used to assess vitamin D status in 
serum or plasma [68]. However, 25(OH)D is much more strongly bound to the plasma 
protein vitamin D binding protein (VDBP) compared to the parent form [69], and therefore 
cellular internalization in different tissues may become considerably restricted [70]. Another 
concern often brought up when interpreting observational studies in the vitamin D field 
relates to the lack of data regarding circulating concentrations of free 25(OH)D, as the 
majority of 25(OH)D  is normally bound to VDBP in the circulation. The concentration of 
VDBP is one of the key determinants of the amount of free 25(OH)D, which – according to 
the ‘free hormone hypothesis’ - is the portion of total 25(OH)D that can be biologically active 
[71]. However, some studies imply that 25(OH)D complexed to VDBP can enter cells via 
receptor-mediated endocytosis to activate the VDR pathway [72]. It is known that black 
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for TB in non-Hispanic black Americans is eight times higher than for non-Hispanic whites 
[74]. The results from a highly cited study suggested that also levels of VDBP were lower in 
black Americans, which would result in similar levels of free 25(OH)D in black compared to 
white Americans [75]. However, a more recent report found a technical flaw in the ELISA-
method used to measure serum levels of VDBP and instead show that the levels of free 
25(OH)D were lower in black Americans compared to Caucasians [76]. With regard to TB, 
an in vitro study has reported that VDBP attenuates the ability of 25(OH)D to support 
antimicrobial responses, suggesting that concentrations of free 25(OH)D may have 
physiological relevance for mononuclear phagocyte function [77]. However, in vivo studies 
investigating the clinical significance of circulating concentrations of free and bioavailable 
vitamin D metabolites in patients with TB are still lacking.  
 
Of importance is also the dosing of vitamin D in both health and disease, which currently is 
an area of debate. While the US Institute of Medicine (IOM) suggest that vitamin D levels 
>50 nmol/l is sufficient [78], the Endocrine Society instructs that >75 nmol/l is sufficient, 50-
75 nmol/l is still insufficient and levels <50 nmol/l are defined as deficiency [79, 80]. To 
reach these blood levels of vitamin D, IOM recommends that an average daily intake of 400–
800 IU is adequate for most individuals [78, 81], while the Endocrine Society suggests that a 
higher daily intake of 1000–10.000 IU may be required to maintain a sufficient vitamin D 
status [82]. The discrepancy in these opinions may be partly due to the fact that different 
25(OH)D concentrations may be required to prevent or treat different conditions. Originally, 
a daily dose of 400 IU was given to sustain bone health and prevent rickets in children [83]. 
If baseline vitamin D status is low, supplementation with low doses may be efficient to 
reduce susceptibility to certain upper respiratory tract infections [84]. However, sometimes 
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with optimal protection against respiratory pathogens [85]. A daily intake of 1120–1680 IU 
was required to maintain 25(OH)D levels above 75 nmol/l (30 ng/ml) in blood, while vitamin 
D deficient individuals needed 5.000 IU to reach these blood levels [86]. In the mid-20th 
century, case series reported that vitamin D2 given at doses of 100-150.000 IU/day promoted 
clinical recovery or cure in patients with lupus vulgaris (cutaneous TB) [87]. Such high 
pharmacological doses are more often administered less frequently as bolus doses, i.e. 
weekly, monthly or even yearly. Although it is convenient to give patients large bolus doses 
of vitamin D, these are not effective in achieving sustained elevation in circulating 25(OH)D 
concentrations if widely spaced  [88]. Instead, as recently demonstrated in a meta-analysis of 
the effects of vitamin D in acute respiratory infections, a physiological dosing regimen of 
daily or weekly vitamin D is more likely to afford protection [8]. This way vitamin D could 
be readily used for cellular uptake in tissues and promote 1,25(OH)2D conversion and VDR 
signaling that are required to reach clinical effects in different disease conditions.  
 
Whereas vitamin D dosing and metabolism in vivo are important factors to consider when 
designing potential vitamin D supplementation regimens for the prevention or treatment of 
TB, many case-control studies performed in diverse geographical regions have also tried to 
elucidate whether vitamin D deficiency is associated with progression of active TB disease 
[9-13]. Since UVB radiation in sunshine is required for cutaneous synthesis, circulating 
25(OH)D concentrations exhibits considerable seasonal variation outside of the tropics, 
through winter and spring. Vitamin D deficiency has also been reported to be common in 
certain groups such as breast-feeding mothers and their infants, young adults as well as 
elderly and people with dark skin [89-92]. A significant increase in TB incidence was 
observed in South African children during late winter and early spring, reported from 1983-
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Cape Town, South Africa, that were inversely correlated to corresponding fluctuations in 
vitamin D status [11]. Vitamin D deficiency was highly prevalent among black Africans in 
this setting and correlated with susceptibility to active TB in both HIV-negative and HIV-
positive individuals [11]. Increased melanisation of the skin affords physiological protection 
against adverse effects of UVB (skin cancer and degradation of folate), but it may increase 
the risk of vitamin D deficiency where UVB is limited [92, 94]. A high melanin content in 
the skin has been reported to reduce the capacity of UVB-exposed skin to produce 25(OH)D 
[95]. To synthesize the same amount of vitamin D, dark-skinned individuals require three to 
four times longer sun exposure than light-skinned persons because melanin efficiently 
absorbs UVB radiation [96]. Accordingly, two studies reported skin pigmentation as a 
significant predictor of vitamin D deficiency in Eastern and Northern Africa, respectively 
[97, 98]. Africans have lower neutrophil counts and lower circulating concentrations of 
antimicrobial peptides compared to south Asian and Caucasian people [99]. In addition, 
serum from African-American individuals was less effective than serum from Caucasians in 
supporting vitamin D-dependent induction of LL-37 mRNA in monocytes in vitro [9], a 
finding that may be attributable to ethnic differences in serum 25(OH)D content and/or 
VDBP genotype. As a consequence, African individuals may be more susceptible to TB [60, 
100], perhaps due to a suboptimal induction of LL-37 and other important antimicrobial 
effector molecules at the site of Mtb infection in the lung [25].  
 
Studies on the association between low levels of 25(OH)D and the risk of infection can 
always be criticized for reverse causality. While several studies have found a clear 
relationship between vitamin D deficiency and active TB, other studies have not observed 
such an association [101]. Thus, it is difficult to generalize these findings and conclude if 
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whether vitamin D deficiency in TB is a cause or consequence of clinical disease. A meta-
analysis of observational studies between 1980-2006, found a 70% probability that a healthy 
individual would have higher 25(OH)D serum levels than a patient with untreated TB [102]. 
It has also been proposed that the susceptibility to TB is dependent on the degree of vitamin 
D deficiency, as serum vitamin D levels ≤ 25 nmol/l was significantly associated with an 
increased risk of TB, while 26-50 nmol/l provided an intermediately high TB risk and a range 
of 51-75 nmol/l did not enhance TB susceptibility [103]. To date, numerous studies have also 
been designed to address how genetic variations in proteins involved in the vitamin D 
signaling pathway may affect the susceptibility to TB, i.e. polymorphisms in the VDR or 
VDBP [12, 104]. Meta-analyses suggest that the VDR FokI polymorphism is associated with 
an increased risk of pulmonary TB in East Asians [105], while the t allele of the VDR TaqI 
polymorphism is significantly associated with an increased TB risk in South and West Asians 
[106]. Moreover, the Gc2/2 genotype of the VDBP was strongly associated with development 
of active TB in vitamin D deficient Gujarati Asians [104], while no such association was 
found in a South Asian cohort who presented an independent correlation between vitamin D 
deficiency and susceptibility to active TB [107].  
 
Altogether, many studies support the notion that low 25(OH)D levels and polymorphisms in 
specific vitamin D signaling molecules can contribute to an enhanced susceptibility to active 
TB, at least in certain populations. Further studies exploring the association of bioavailable 
versus total 25(OH)D with susceptibility to Mtb infection or disease and how vitamin D 
metabolism changes with disease development, may provide valuable information about 
cellular vitamin D uptake and also learn us how to implement an effective dosing regimen. 
But altogether, can an improved vitamin D status in patients with pulmonary TB enhance 
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Randomised controlled trials investigating the effects of vitamin D supplementation in 
active TB 
Despite convincing in vitro data supporting an overall positive effect of vitamin D on innate 
immune functions and protection against TB, few larger clinical trials support such an effect 
using a microbiological outcome. A total of fifteen randomised placebo-controlled trials 
evaluating effects of adjunctive vitamin D on response to antimicrobial therapy for TB have 
been published to date (summarised in Table 1). Twelve of these clinical trials had clinical 
primary outcomes. Morcos and colleagues investigated the effects of 0.025 mg (1.000 IU) 
vitamin D daily in a 24 children in Egypt receiving antimicrobial therapy for TB, and showed 
no effect on body weight or resolution of symptoms [108]. Nursyam and colleagues 
subsequently conducted a trial of a daily dose of 0.25 mg (10.000 IU) vitamin D in 67 
pulmonary TB patients in Indonesia [109]. In this study, adjunctive vitamin D enhanced 
sputum smear conversion at 6 weeks after initiation of antimicrobial therapy (34/34 vs. 25/33 
smear-converted in intervention vs. control arm at 6 weeks, p=0.002), but no effect of the 
intervention was seen at 8 weeks [109]. The vitamin D status of participants was not assessed 
at either baseline or follow-up in this study, and details of safety monitoring, including 
monitoring of serum calcium concentrations, were not reported. Wejse and colleagues 
randomised 365 adult TB patients in Guinea-Bissau to receive three doses of 2.5 mg (100.000 
IU) vitamin D3 or placebo at initiation of antimicrobial therapy, and again at 5 and 8 months 
[110]. The intervention had no effect on the primary outcome measure, which was a 
composite clinical TB score [110]. Mean serum 25(OH)D concentrations at baseline showed 
generally sufficient levels of 78 nmol/L (31.2 ng/ml) versus 79 nmol/L (31.6 ng/ml) in the 
intervention compared to the control group [110]. Notably, the serum levels of 25(OH)D did 
not increase in the intervention group after vitamin D supplementation [110], which together 
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conducted in 60 TB patients in Iran who were given a single oral dose (11.25 mg) of 
adjunctive vitamin D, reported a favorable effect on a similar TB score [111]. 
 
Martineau and colleagues investigated the effect of four 2-weekly doses of 2.5 mg (100.000 
IU) vitamin D on time to sputum culture conversion in 146 patients with smear-positive 
pulmonary TB in the UK [58]. A 79 nmol/l (31.6 ng/ml) increase in serum 25(OH)D was 
seen among participants in the intervention arm of the study, which was associated with a 
trend towards faster sputum culture conversion (p=0.14) [58] and accelerated resolution of 
inflammatory responses in peripheral blood [57]. This finding was echoed by a subsequent 
study conducted in mice [112]. A sub-group analysis revealed that adjunctive vitamin D 
significantly hastened sputum culture conversion by more than 17 days in participants with 
the tt genotype of the TaqI VDR polymorphism (hazard ratio 8.09, 95% CI 1.36-48.01; 
p=0.02) [58], indicating that immunomodulatory effects of vitamin D supplementation are 
dependent on VDR genotype. Salahuddin and colleagues investigated the effects of two large 
intramuscular doses (600.000 IU) of vitamin D3 in 259 adults with pulmonary TB in Pakistan 
and found that the intervention enhanced weight gain and resolution of chest radiograph 
infiltrates, but did not influence sputum smear conversion [113].  
 
Two subsequent trials employed a 2x2 factorial design to test the effects of vitamin D 
combined with other potential host-directed therapies. Ralph and colleagues investigated 
effects of a relatively low dose of vitamin D3 (2 x 1.25 mg) and the nitric oxide precursor L-
arginine in 200 adults in Indonesia, and reported no effect of either intervention on sputum 
culture conversion [114]. Mily and colleagues investigated the effects of daily vitamin D3 
(5.000 IU) in conjunction with a twice-daily oral dose of 4-phenylbutyrate (500 mg) in 288 
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conversion at eight weeks when all participants receiving vitamin D were compared with 
placebo [115]. Another study with vitamin D and phenylbutyrate conducted in Ethiopia using 
a similar dosing regimen to 348 pulmonary TB patients, showed a significant effect on 
clinical recovery assessed as a reduction in a composite TB score at week 8 compared to 
baseline (Clinicaltrials.gov ID: NCT01698476, invited revision). However, no effect on 
longitudinal sputum smear or culture conversion could be detected. 
 
In the largest trial conducted to date, Datta and colleagues investigated effects of high-dose 
intramuscular vitamin D3 and reported a trend towards reduced TB symptom score and higher 
rates of sputum smear conversion in participants randomised to the intervention arm of the 
trial: however, P values for inter-arm comparisons were not presented [116]. Three 
subsequent trials, one in the Republic of Georgia ([117], n=199), one in India ([118], n=247) 
and one in Mongolia ([59], n=390) investigated effects of high-dose oral vitamin D3 on 
sputum culture conversion, and reported no significant effect on this outcome.  
 
Three trials listed in Table 1, had biochemical primary outcomes, ie. calcium levels: two 
reported no hypercalcaemia in TB patients receiving either 0.125 mg (5.000 IU) vitamin D 
daily [119] or a single oral dose of 2.5 mg (100.000 IU) vitamin D [120], and one reported 
hypercalcaemia occurring in 19/30 TB patients receiving daily doses of 0.01 – 0.095 mg (400 
– 3.800 IU) vitamin D daily [121]. However, this third study, by Narang and colleagues, also 
reported that a daily dose of 0.06 mg (2.400 IU) vitamin D elevated mean serum calcium  in 
healthy controls – a finding which contrasts with other studies demonstrating that identical 
[122] or considerably higher [123] doses of vitamin D do not induce hypercalcaemia in 
healthy people. It is possible, therefore, that the actual doses of vitamin D administered in 
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In summary, clinical trials of adjunctive vitamin D supplementation in patients with active 
TB have reported conflicting results. Meta-analysis of individual participant data from 
these studies has the potential to identify whether this heterogeneity arises from inter-trial 
differences in participant characteristics that may modify response to vitamin D 
supplementation, such as baseline vitamin D status or drug susceptibility. Such a meta-
analysis is on-going: 
(http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42015020288), and 
its findings may identify sub-groups of TB patients who may derive benefit from 
adjunctive vitamin D. Overall, however, the conflict between largely positive in vitro data, 
and largely null in vivo data from treatment trials, presents something of a conundrum. 
What can we learn from these experiences in the continued design of new treatment and 
prevention trials? 
  
Clinical evidence for positive effects of vitamin D in acute respiratory tract infections: 
Relevance for continued research on vitamin D to prevent TB 
There are several potential explanations for the disconnect between positive results from in 
vitro studies and null results from treatment studies investigating the adjunct effects of 
vitamin D in TB. Some lessons can be learned from observing the role of vitamin D in the 
prevention of acute respiratory infections (ARIs) that has been intensively investigated during 
recent years. The rationale for a protective effect of vitamin D against viral and bacterial 
infections in the respiratory tract originates from several pieces of evidence. Similar to TB, 
results from observational studies support that vitamin D deficiency is a risk factor for acute 
respiratory infections [124]. There is a clear seasonal variation in the prevalence of ARI, 
peaking in the winter time when serum levels of 25(OH)D were low [125]. However, similar 










This article is protected by copyright. All rights reserved. 
poor health in general, which is commonly associated with low vitamin D status due to lack 
of sun-exposure and/or an insufficient diet. In parallel to observational studies, numerous 
experimental models have supported a protective role for vitamin D against respiratory 
pathogens. For example, high local expression of the vitamin D converting enzyme, 
CYP27B1, has been found in bronchial epithelial cells, which promotes the generation of 
1,25(OH)2D that could alter immune function in the lung [126]. Consequently, vitamin D 
induced the expression of antimicrobial LL-37 in bronchial epithelial cells that exhibited 
activity against respiratory syncytial virus (RSV), rhinovirus as well as different airway 
bacteria [127-129]. In addition, vitamin D dampened inflammatory cytokine release from 
RSV-infected airway epithelial cells without increasing viral replication, which suggests that 
vitamin D-signalling ameliorate disease progression in virus-infected individuals [130]. 
 
The overall effect of vitamin D supplementation on the risk of ARIs was recently assessed in 
a meta-analysis using individual patient data obtained from 10,933 patients who participated 
in 25 different trials [8]. This meta-analysis also enabled detailed subgroup analysis of the 
various factors involved in the outcome of the included randomised trials. The results showed 
that vitamin D supplementation protected against ARI’s overall, but that the effect was most 
pronounced in individuals with severe vitamin D deficiency (serum 25(OH)D < 25 nmol/l) at 
baseline, who received a daily or weekly dose, i.e. no bolus dosing [8]. Accordingly, the 
numbers needed to treat (NNT) in order to prevent one person from getting an ARI was 
considerably lower for individuals with vitamin D levels < 25 nmol/l who received daily or 
weekly vitamin D supplementation (NNT=4) compared to the all included study participants 
(NNT=33). This study identified two factors that independently modified the effect of 
vitamin D supplementation on the risk of ARIs: baseline vitamin D status and dosing 










This article is protected by copyright. All rights reserved. 
beneficial effect of vitamin D supplementation in common ARIs and asthma, but found little 
effect against other non-skeletal outcomes, TB included [131]. Of note, in contrast to TB and 
several other conditions, the number of trials and amount of patient data available in vitamin 
D trials aiming to prevent ARIs are relatively high, which enables adequately powered 
subgroup analyses.    
 
Can the findings on beneficial effects of vitamin D in ARIs teach us something about vitamin 
D-mediated effects in TB? Several relevant parallels can be made, highlighting differences as 
well as similarities. First, in the studies on ARIs, vitamin D has been given as a preventive 
intervention and not as a therapeutic drug. This is a major difference compared to most TB 
trials where vitamin D has been administered as adjunctive therapy together with standard 
anti-TB drugs to primarily sputum-positive patients with pulmonary TB. Although drug-
susceptible TB has to be treated with multiple drugs every day for months, there is a rapid 
bactericidal effect already within the first few weeks of standard treatment characterized by 
rapid sputum conversion, radiological improvement and clinical recovery in most patients 
[132, 133]. This will probably mask relatively modest antimicrobial effects induced by 
vitamin D that were apparent in the pre-antibiotic era [134] This notion would be consistent 
with most clinical evidence showing a null effects in treatment studies (Table 1). The 
findings from ARI studies suggest that we might be more likely to detect an effect of vitamin 
D supplementation in TB prevention than for adjunctive treatment. Low 25(OH)D levels may 
enhance the risk of latent TB [135, 136] as well as progression of active TB [11, 137]. 
However, trials of vitamin D to prevent acquisition or reactivation of latent Mtb infection are 
considerably more challenging to conduct than those investigating ARIs, since event rates are 
much lower: thus, sample sizes need to be much larger, and follow-up much longer, in order 










This article is protected by copyright. All rights reserved. 
Second, the ARI studies suggest that vitamin D supplementation is most beneficial if 
administered with short intervals, i.e. not as large bolus doses [8]. Interestingly, daily or 
weekly vitamin D could prevent ARIs particularly in vitamin D deficient patients (< 25 
nmol/l), but also in individuals with higher (> 25 nmol/l) 25(OH)D levels at baseline [8]. In 
contrast, less frequent bolus dosing failed to prevent ARIs in the subjects, regardless of 
vitamin D status [8]. Administration of high-dose bolus vitamin D results in large fluctuations 
in circulating 25(OH)D concentrations [65], which may lead to a dysregulation of 1-
hydroxylase activity that ultimately reduce the conversion to active 1,25(OH)2D available in 
the tissues [138]. This seemingly paradoxical phenomenon may be caused by a delay in the 
metabolic feed-back mechanism induced in responses to widely fluctuating 25(OH)D levels 
in blood, when the body is trying to adapt to interchangeably high and low concentrations of 
25(OH)D [138]. Thus, although it is convenient to give patients large bolus doses of vitamin 
D to increase adherence, lower doses given more often may be required to maintain stable 
levels of 25(OH)D that could induce protective immunity and reach desired clinical effects. 
Altogether, these results suggest that a widely spaced bolus dosing regimen that has been 
frequently used to study the effects of vitamin D in randomised TB trials, should be avoided 
in trials of vitamin D for TB prevention.  
 
Third, as described above, vitamin D supplementation appears to be more effective in 
preventing ARIs in individuals with profound vitamin D deficiency, while the positive effects 
may be less pronounced if baseline vitamin D status is high [8]. This is in line with sub-group 
analyses performed in two vitamin D supplementation trials indicating clinical improvement 
and enhanced sputum-smear conversion, particularly in TB patients with low baseline 
vitamin D levels [113] (Clinicaltrials.gov ID: NCT01698476, invited revision). This is 
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to its replacement. Ideally, screening TB patients for vitamin D deficiency before inclusion in 
randomised vitamin D trials may enhance the likelihood to detect significant effects. 
However, there are both ethical and logistic problems associated with such an approach that 
have to be carefully considered.  
 
Potential future approaches: Vitamin D supplementation to treat or prevent TB in 
certain high-risk groups 
Current clinical evidence points to the fact that vitamin D-mediated effects in TB are slight or 
absent when administrated to a broad range of patients receiving antimicrobial therapy for 
pulmonary TB. But since vitamin D has documented antimicrobial as well as anti-
inflammatory properties in experimental models, the rationale to use this cheap and safe 
intervention against TB in some form is still attractive. Most of the intervention trials 
performed with vitamin D in TB are too small to allow sub-group analyses to assess the 
importance of different variables as potential effect modifiers such as low baseline vitamin D 
status, HIV infection or other co-morbidities, MDR-TB or advanced cavitary TB disease, etc. 
These groups may be relevant to target in future treatment trials. Accordingly, a key area 
where adjunctive vitamin D could be useful, is in patients infected with MDR-TB. Since 
standard drugs are not expected to be as efficient, any true effect of vitamin D may be 
unmasked and should be possible to find in a reasonably large clinical trial. There are studies 
where MDR-TB patients were included, revealing a trend towards enhanced improvement of 
vitamin D in MDR-TB patients [59, 117]. But in most trials, MDR-TB has usually been an 
exclusion criterion or the numbers of MDR-TB patients in individual studies have not been 
large enough to make definite conclusions. Given the emerging threat of MDR-TB in certain 
regions in i.e. South-Africa and Eastern Europe, it should be possible to design a larger study 
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TB patients with other co-morbidities including HIV-infection and diabetes. Here, daily 
supplementation of vitamin A (2000 IU), vitamin D (400 IU) or the combination was planned 
to be provided to 400 patients with active pulmonary TB and type 2 diabetes in Qingdao, 
China, assessing if adjunct anti-TB treatment could ameliorate glucose metabolism and 
improve immune and nutritional status [139] (Trial Registration: ChiCTR-TRC-12002546). 
The current progress of this study is unknown. 
The effects of adjunctive therapy with vitamin D in TB may also be enhanced by 
combination treatment with other drugs or compounds such as arginine [114], phenylbutyrate 
[115] or statins [140], that may exert synergistic effects with vitamin D. In this context, the 
interaction of vitamin D with standard anti-TB drugs should be investigated in more depth, 
both in vitro and in vivo, as several studies suggest that anti-TB drugs can alter vitamin D-
mediated immune pathways. Apart from their bactericidal or bacteriostatic actions, standard 
antibiotics can also modulate host immune responses such as phagocytosis, chemotaxis, 
antigen presentation, cytokine secretions and autophagy [141-143]. Furthermore, intensive-
phase treatment with rifampicin and isoniazid have been shown to reduce baseline vitamin D 
levels in the majority of treated TB patients, which suggests that standard treatment alone 
may promote vitamin D deficiency or worsen an already low vitamin D status [144]. 
 
Whereas there is a need to reconsider the current approaches and try other innovative study 
designs, one approach that has yet to be formally tested in clinical trials is whether vitamin D 
can prevent Mtb infection and/or control latent TB and prevent the conversion to active, 
sputum-positive TB. One previous trial conducted in 120 Mongolian schoolchildren, 
concluded that 6 months vitamin D supplementation (800 IU/day) resulted in significantly 
improved vitamin D status while a trend towards reduced number of tuberculin skin 
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occurred in children who remained vitamin D deficient [145], suggesting that vitamin D 
supplementation indeed may prevent latent TB infection. As a follow up to this pilot study, a 
much larger trial has been initiated, the Vitamin D supplementation in TB prevention trial, 
which aims to investigate the preventive role of vitamin D in 8000 school children in a 
similar high transmission setting in Mongolia (Clinicaltrials.gov ID: NCT02276755). Here, 
the acquisition of latent TB, assessed using the Mtb-specific test, Quantiferon-TB Gold In-
Tube (QFT) test, as well as the development of active TB, will be monitored after three years 
of weekly vitamin D (14.000 IU). The notion is that children with the lowest vitamin D status 
at baseline will gain most from the intervention. Another large ongoing clinical trial is the 
VidiKids trial (Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren), 
conducted in Cape Town, South Africa, to determine whether a weekly oral dose (10.000 IU) 
of vitamin D3 will reduce the risk of latent TB among 5.400 QFT-negative primary 
schoolchildren, who are followed for three years (Clinicaltrials.gov ID: NCT02880982). The 
large size of these ongoing trials will probably increase the likelihood to detect differences in 
QFT conversion between vitamin D and placebo groups. However, QFT is not a validated 
gold standard to monitor acquisition of Mtb infection, and will only detect an immune 
response towards Mtb bacteria but not the presence of bacteria in the lung. Moreover, the 
QFT test has technical limitations that may impede overall analysis, highlighting the need for 
new read-out systems used to monitor latent TB.  
 
Two on-going randomised trials are investigating whether vitamin D supplementation might 
have a role in the prevention of incident or recurrent TB disease. The TOV4 trial (Trial of 
Vitamin D in HIV progression) have recruited 4.000 HIV-infected Tanzanian individuals 
who stated antiretroviral treatment and simultaneously were provided weekly (50.000 IU) and 
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cause mortality and incidence of active TB  (Clinicaltrials.gov ID: NCT01798680). The 
ResolveD-TB trial (Vitamin D to Resolve Inflammation After TB), is a small proof-of-
concept study that aims to determine if vitamin D can prevent recurrent TB by enhanced 
resolution of pulmonary inflammation detected using 18F-FDG PET-CT scanning 
(Clinicaltrials.gov ID: NCT03011580). In this pilot study, 40 vitamin D-deficient patients 
with baseline 25(OH)D levels <50 nmol/l will be included if they have residual pulmonary 
lesions detected on PET-CT scanning after 6-months standard anti-TB treatment, to receive 
high-dose daily vitamin D (9.600 IU/day) or placebo for 8 weeks. The presence of PET-hot 
intra-thoracic lesions at the end of TB treatment has been posited as a biomarker for risk of 
post-treatment relapse [146]. If vitamin D supplementation can suppress PET-CT-detectable 
intra-thoracic inflammation in this patient group, it would provide a rationale to progress to a 
phase 3 randomised trial of vitamin D supplementation to prevent recurrrent TB. 
 
Concluding remarks 
Vitamin D is an immunomodulatory micronutrient that simultaneously supports anti-
mycobacterial and anti-inflammatory activity in vitro. Attempts to use the 
immunomodulatory properties of vitamin D to treat pulmonary TB can be traced back to the 
19
th
 century. Despite vitamin D deficiency being common in individuals with active TB, 
clinical and bacteriological results from randomised controlled trials of adjunctive vitamin D 
supplementation in patients receiving antimicrobial therapy for pulmonary TB have not 
demonstrated consistent clinical benefits, despite showing immunomodulatory activity. This 
may represent ‘masking’ of favourable immunomodulatory activity by the actions of potent 
antimicrobial therapy in the context of drug-sensitive disease. Adjunctive vitamin D may yet 
have potential to benefit sub-groups of patients in whom antimicrobial therapy is less 
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area. However, given the lack of consistent favourable results from trials of adjunctive 
vitamin D in TB treatment, increasing attention is focusing on the potential for vitamin D 
supplementation to prevent acquisition or reactivation of latent Mtb infection. Trials of 
vitamin D for the prevention of acute respiratory infections suggest that protective efficacy of 
this intervention is greatest when vitamin D is given in daily or weekly doses to individuals 
with low 25(OH)D levels at baseline. These findings have the potential to inform the design 
of future trials of vitamin D supplementation for the prevention and treatment of TB.   
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Table 1 Randomised placebo-controlled trials investigating effects of adjunctive 






Vitamin D dose 
administered 
Effect on serum 
25(OH)D 
concentration  





0.025 mg (1.000 IU) 
daily  






0.25 mg (10.000 IU) 
daily  
Not reported  Smear conversion: increased 
rate at 6 wks  
Martineau 
2009 [120] 
25 adults, UK  1 x 2.5 mg (100.000 
IU) D2 @ 0 months  
22 nmol/L (8.8 
ng/ml) increase in 
active arm  
Serum 25(OH)D: small increase 






3 x 2.5 mg (100.000 
IU) D3 @ 0/5/8 
months  
25 nmol/L (10 
ng/ml) increase 
both arms  





4 x 2.5 mg (100.000 
IU) D3 @ 0/2/4/6 
weeks 
79 nmol/L (31.6 
ng/ml) increase in 
active arm 
Culture conversion: no effect in 
study population as a whole, but 
effect seen in subgroup with tt 






2 x 15 mg D3 i.m. @ 
0/4 weeks 
170 nmol/L ↑ in 
active arm 
Body weight ↑, CXR infiltration ↓ 
with vitamin D. Smear 





2 x 1.25 mg D3 p.o. @ 
0/4 weeks (factorial 
with L-arginine) 





125 mg D3 p.o. daily 
for 2 months (factorial 
with phenylbutyrate) 
80 nmol/L ↑ in 
active arm 
Culture conversion: 123/127 
(97%) vs. 110/122 (90%) culture 
converted at 8 wk in D3 vs. 
placebo arms respectively 





2 x 15 mg D3 i.m. @ 
0/3 months 
Not ↑ in active 
arm, but ↓ in 
control arm 
Trend towards lower ‘TB score’ 
and higher rates of smear 






3 x 1.25 mg D3 per wk 
for 8 wk, then 1.25 mg 
D3 alternate wks for 8 
wk 
200 nmol/L ↑ in 
active arm 
Culture conversion: no effect. 






4 x 2.5 mg (100.000 
IU) D3 @ 0/2/4/6 
weeks 
14 nmol/L ↑ in 
active arm 





4 x 3.5 mg (100.000 
IU) D3 @ 0/2/4/6 
weeks 
139 nmol/L ↑ in 
active arm 





1 x 11.25 mg @ 0 
months 
Not reported TB score: reduced in 





0.125 mg (5.000 IU) 
daily  





0.01-0.095 mg (400 -
3.800 IU) daily  
Not reported  Serum calcium: hypercalcaemia 
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Figure captions 
 
Fig. 1 Schematic illustration of vitamin D metabolism and signaling using the endocrine as 
well as the paracrine systems. Vitamin D is produced in the skin upon UVB exposure or 
ingested in the diet. Conversion to the 25(OH)D proform, which is the major circulating 
metabolite, occurs primarily in the liver. 25(OH)D in serum is present either in its free form 
or bound to the VDBP. 1-alpha hydroxylation of 25(OH)D occurs in the kidney but also in 
different immune cells, for production of the active metabolite 1,25(OH)2D. 1,25(OH)2D 
binds to the intracellular VDR to form a transcription factor complex that can regulate the 
expression of different target genes involved in the immune response to TB. 
 
Fig 2. Effects of vitamin D on innate and adaptive immune responses. Active 1,25(OH)2D up-
regulates expression of antimicrobial peptides such as LL-37, hBD-1 as well as oxidative 
stress, autophagy and IL-1 in Mtb-infected macrophages. It also down-regulates 
differentiation and activation of DCs, which may result in expansion of Treg cells that can 
inhibit effector Th1 responses. In addition, 1,25(OH)2D has direct inhibitory effects on the 
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